Podcast
0.25 CME Credit
Starting Medications for T2DM: When Metformin Isn’t the First Choice - Frankly Speaking Ep 403Guest: Alan M. Ehrlich, MD, FAAFP
Music Credit: Richard Onorato
Recorded live at Pri-Med East - The American Diabetes Association (ADA) has updated their standards of care for patients with diabetes. In this episode, we discuss some of the changes in the initial selection of glucose-lowering medications for type 2 diabetes mellitus (T2DM), including when alternatives to metformin may be appropriate. Hear strategies for making personalized, guideline-recommended choices that enhance care for patients with T2DM.
Episode references and resource links:
- Pharmacologic Approaches to Glycemic Treatment. In: American Diabetes Association. Standards of Care in Diabetes2024 - DiabetesCare 2024 Jan 1;47(Suppl 1):S1-S321
Already listened on another platform?
CME/CE Information
0.25 AMA PRA Category 1 Credits™
Release Date: 10/21/2024
Expiration Date: 10/21/2026
Topics
Learning Objectives
- Describe how to select appropriate medications to start treatment for type 2 diabetes mellitus (T2DM) based on specific patient characteristics and comorbidities
- Review factors that place a patient at high risk for atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD)
Faculty
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Alan M. Ehrlich, MD, FAAFP
Associate Professor of Family Medicine and Community Health, University of Massachusetts Medical School,
Executive Editor, DynaMed
Disclosures
Frank J. Domino, MD: Has disclosed no relevant financial relationships.
Alan M. Ehrlich, MD, FAAFP: Has disclosed no relevant financial relationships.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.